aliskiren effective alone and in combination for hypertension
Post on 12-Dec-2016
214 views
TRANSCRIPT
Inpharma 1522 - 28 Jan 2006
Aliskiren effective alone and incombination for hypertension
The results of three phase III trials indicate that theoral renin inhibitor aliskiren* [SPP 100] may be aneffective and well tolerated treatment for hypertension,both as monotherapy and in combination with certainother antihypertensives.
In one trial, aliskiren 150mg administered withamlodipine 5mg provided improved BP control and adecrease in oedema in patients with hypertension.
In another trial, involving 837 patients withhypertension and diabetes mellitus, aliskirenmonotherapy produced double digit decreases insystolic and diastolic BP; when coadministered withramipril, aliskiren was associated with significantadditional decreases in systolic and diastolic BP.Furthermore, aliskiren produced a reduction in drycough when administered with the ACE inhibitor.
In a third trial, aliskiren monotherapy was reported tohave placebo-like tolerability in patients withhypertension treated for > 1 year.* Novartis, Speedel Pharmaceuticals; phase III for hypertension in theUS, Europe and Japan
Speedel Pharmaceuticals Inc. Novartis New Phase III Data With SPP100 (aliskiren,Rasilez) Reconfirms Strong Efficacy and Excellent Safety Profile as Monotherapyand Co-Administration Therapy for Treatment of Hypertension. Media Release :19 Jan 2006. Available from: URL: http://www.speedel.com 809059148
1
Inpharma 28 Jan 2006 No. 15221173-8324/10/1522-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved